Michael Goldberg - 31 Mar 2026 Form 4 Insider Report for CareDx, Inc. (CDNA)

Reporting relationship: Director
Issuer ticker: CDNA
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2026, 16:10:13 UTC
Prior SEC filing: 07 Jan 2026
Next SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Adam Novack, Attorney-in-Fact

Key filing fact

Michael Goldberg filed Form 4 for CareDx, Inc. (CDNA) on 01 Apr 2026.

Key facts

This page summarizes Michael Goldberg's Form 4 filing for CareDx, Inc. (CDNA).
6 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 01 Apr 2026, 16:10.

Change

Previous filing in this sequence was filed on 07 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001366412 Primary reporting owner

Goldberg Michael

Relationship: Director
Address: C/O CAREDX, INC., 8000 MARINA BOULEVARD, 4TH FLOOR, BRISBANE
Signature: /s/ Jeffrey Adam Novack, Attorney-in-Fact
Signature date: 01 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CDNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,255
Change %: +3.3%
Price: $5.02^*
Shares after: 162,716
Date: 31 Mar 2026
Ownership: Direct

CDNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +9,745
Change %: +6%
Price: $4.95^*
Shares after: 172,461
Date: 31 Mar 2026
Ownership: Direct

CDNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,500
Change %: +6.7%
Price: $1.22^*
Shares after: 183,961
Date: 31 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CDNA transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -5,255
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,255
Exercise price: $5.02
Footnotes: F1

CDNA transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -9,745
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,745
Exercise price: $4.95
Footnotes: F2

CDNA transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -11,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,500
Exercise price: $1.22
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

1/12th of the shares subject to the option shall vest on July 16, 2016 and 1/12th of the shares subject to the option shall vest monthly thereafter.

Footnote F2

1/12th of the shares subject to the option shall vest on August 1, 2016 and the shares subject to the option shall vest monthly thereafter through the earlier of the next annual shareholder meeting or July 1, 2017.

Footnote F3

1/12th of the shares subject to the option shall vest on August 13, 2017 and the shares subject to the option shall vest monthly thereafter through July 13, 2018.